Search

Your search keyword '"Andrejak, Claire"' showing total 225 results

Search Constraints

Start Over You searched for: Author "Andrejak, Claire" Remove constraint Author: "Andrejak, Claire"
225 results on '"Andrejak, Claire"'

Search Results

1. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

2. Guidelines for the assessment and management of residual sleepiness in obstructive apnea-hypopnea syndrome: Endorsed by the French Sleep Research and Medicine Society (SFRMS) and the French Speaking Society of Respiratory Diseases (SPLF)

3. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial

4. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

5. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma

6. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

7. Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19

9. Recommandations pour le bilan et la prise en charge de la somnolence résiduelle dans le syndrome d’apnées-hypopnées obstructives du sommeil

10. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

11. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

12. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial

13. French recommendations for the diagnosis and management of lymphangioleiomyomatosis

14. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases

15. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

17. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

18. Differences in HADS and SF-36 scores 1 year after critical illness in COVID-19 patients

19. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

21. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial

22. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTRvariant: a real-world study

24. Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

25. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

26. Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study

32. Les plaintes cognitives du syndrome post-Covid19

33. Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study

35. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial

36. Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials : experience from EU‐Response and conect4children consortia

37. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

38. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study

39. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

41. Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults

42. Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

43. European Respiratory Society Statement on Long COVID-19 Follow-Up

44. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

45. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

47. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

49. No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19

Catalog

Books, media, physical & digital resources